- Home
- OVID
as 05-09-2025 4:00pm EST
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 24.0M | IPO Year: | 2017 |
| Target Price: | $3.03 | AVG Volume (30 days): | 376.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.24 - $3.43 | Next Earning Date: | 05-20-2025 |
| Revenue: | $566,000 | Revenue Growth: | 44.39% |
| Revenue Growth (this year): | -61.07% | Revenue Growth (next year): | 36.11% |
Stock Insider Trading Activity of Ovid Therapeutics Inc. (OVID)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rona Jeffrey A | OVID | CBFO | Feb 26 '25 | Sell | $0.56 | 3,902 | $2,185.12 | 67,973 | |
| ALEXANDER MARGARET A. | OVID | President and COO | Feb 26 '25 | Sell | $0.56 | 5,279 | $2,956.24 | 73,406 |
Latest Ovid Therapeutics Inc. News
OVID Breaking Stock News: Dive into OVID Ticker-Specific Updates for Smart Investing
Zacks
4 days ago
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
GlobeNewswire
a month ago
Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Simply Wall St.
2 months ago
Ovid Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
MT Newswires
2 months ago
Wedbush Adjusts Price Target on Ovid Therapeutics to $3 From $4, Keeps Outperform Rating
Zacks
2 months ago
Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates
GlobeNewswire
2 months ago
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Simply Wall St.
2 months ago
We're A Little Worried About Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate
GlobeNewswire
2 months ago
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
Compare OVID vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OVID Ovid Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.